25 years of unique experience spanning drug discovery, scientific computing and starting new ventures. Co-founder and CSO of Emiliem, Inc. focused on discovering and developing novel kinase inhibitors for oncology and other indications. Successfully raised seed-capital and discovered novel multiple-kinase inhibitors.

Developed and implemented a cost-effective collaborative business model to implement all aspects of drug discovery and development. Successfully negotiated and licensed exclusive rights to a compound from NIH in the mTOR pathway for proliferative and other disorders and developed a CRADA.

Led a team at Pfizer/Pharmacia/Sugen to map the human kinome which has since then served as a platform for kinase-related research. Experience in leading cross-functional teams across multiple sites in pharmaceutical and biotechnology industries. Guest lecturer for a computational toxicology course at UC Berkeley for the past three years.